TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14671184

Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg/d)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Risperidone (4 mg/d)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 11328775

Group type: EXPERIMENTAL
Intervention: Roxithromycin 300 mg/day
Number of subjects: 9
Study: 9041573

Group type: EXPERIMENTAL
Intervention: Ondansetron (0.1 mg.kg‐1, maximum 4 mg)
Number of subjects: 427
Study: 7949641

Group type: EXPERIMENTAL
Intervention: L-thyroxine (L-T4) therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 34
Study: 3281930

Group type: EXPERIMENTAL
Intervention: Adinazolam
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 31669068

Group type: EXPERIMENTAL
Intervention: 10% TXA mouthwash
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study: 29149145

Group type: EXPERIMENTAL
Intervention: Endoscopic Epidural Laser Decompression (EELD)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Transforaminal Epiduroscopic Laser Annuloplasty (TELA)
Number of subjects: 97
Study: 26712288

Group type: EXPERIMENTAL
Intervention: Topical application of Acacia nilotica paste
Number of subjects: 24

Group type: COMPARATOR
Intervention: Topical application of povidone-iodine solution
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Overall mortality rate
Number of subjects: 24
Study: 23183521

Group type: EXPERIMENTAL
Intervention: Lead-in telaprevir arm (4 weeks of PegIFN-α-2a and ribavirin followed by 12 weeks of telaprevir plus PegIFN-α-2a/ribavirin)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Lead-in telaprevir arm
Number of subjects: 240
Study: 21788077

Group type: EXPERIMENTAL
Intervention: Latanoprost ophthalmic solution 0.005% administered once daily in 1 or both eyes for ≥2 weeks.
Number of subjects: 47
Study: 19366977

Group type: EXPERIMENTAL
Intervention: Customized feedback to patients
Number of subjects: 3703

Group type: EXPERIMENTAL
Intervention: Customized feedback to physicians
Number of subjects: 3703

Group type: EXPERIMENTAL
Intervention: Customized feedback to both patients and physicians
Number of subjects: 3703

Group type: COMPARATOR
Intervention: No customized feedback (control group)
Number of subjects: 3703

Group type: EXPERIMENTAL
Intervention: Customized feedback to patients and/or physicians
Number of subjects: 3703
Study: 16951643

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) 800/200 mg once daily
Number of subjects: 190

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) 400/100 mg twice daily
Number of subjects: 190
Study: 15560809

Group type: EXPERIMENTAL
Intervention: Finger brush (I‐Brush)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Manual toothbrush (Butler GUM 311)
Number of subjects: 37
Study: 11738748

Group type: EXPERIMENTAL
Intervention: Ty21a(pDB1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ty21a
Number of subjects: 12
Study: 9416190

Group type: EXPERIMENTAL
Intervention: Sterile catheterization
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nonsterile catheterization
Number of subjects: 29
Study: 8352817

Group type: EXPERIMENTAL
Intervention: Nifedipine controlled-release formulation (Corinfar retard dragees)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Reference preparation
Number of subjects: 22
Study: 29935905

Group type: EXPERIMENTAL
Intervention: Surgical drains present during surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duration of drainage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Number of drains used
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type of drains (open versus closed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical division and duration of surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wound class
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Location of drains
Number of subjects: 0
Study: 30514159

Group type: EXPERIMENTAL
Intervention: Prosocial behavior
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Antisocial behavior
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control
Number of subjects: 102
Study: 27338942

Group type: EXPERIMENTAL
Intervention: Lymphatic Drainage (LD)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Traditional Massage (TM)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Waiting Group (WG)
Number of subjects: 64
Study: 24548413

Group type: EXPERIMENTAL
Intervention: Novel topical cream that selectively filters nontherapeutic wavelengths of UVB from natural sunlight
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22872692

Group type: EXPERIMENTAL
Intervention: Leptin replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (healthy individuals)
Number of subjects: 0
Study: 20552794

Group type: EXPERIMENTAL
Intervention: Cytoflavin
Number of subjects: 30
Study: 18639791

Group type: EXPERIMENTAL
Intervention: Student Bodies 2 (SB2), a 16-week cognitive-behavioral program
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Student Bodies 2 (SB2)
Number of subjects: 80
Study: 15627183

Group type: EXPERIMENTAL
Intervention: 3.0 T MRI
Number of subjects: 19

Group type: COMPARATOR
Intervention: 1.5 T MRI
Number of subjects: 19
Study: 12011682

Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 420

Group type: COMPARATOR
Intervention: Tap/Biopsy
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Immediate Vitrectomy
Number of subjects: 420
Study: 10078401

Group type: COMPARATOR
Intervention: 4 mg ondansetron i.v.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combination of 4 mg ondansetron and 8 mg dexamethasone i.v.
Number of subjects: 51
Study: 7735342

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Naltrexone plus psychotherapy
Number of subjects: 1

Group type: COMPARATOR
Intervention: Psychotherapy alone
Number of subjects: 1
Study: 2160758

Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg/day for 6 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 14
Study: 7382535

Group type: EXPERIMENTAL
Intervention: Group 1 (0.25 mg/kg hydralazine)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Group 2 (0.5 mg/kg hydralazine)
Number of subjects: 23
Study: 30738699

Group type: EXPERIMENTAL
Intervention: Frontal slow wave EEG power in UHR individuals
Number of subjects: 44

Group type: COMPARATOR
Intervention: Frontal slow wave EEG power in UHR-P vs UHR-NP
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Frontal slow wave EEG power following transition to psychosis
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Delta frequency power correlation in UHR group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Frontal delta or theta power and functioning
Number of subjects: 44
Study: 29276777

Group type: EXPERIMENTAL
Intervention: Dentist-provided treatments (glutaraldehyde/HEMA compounds, oxalates, bonding agents)
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Dentists' advice and counseling regarding oral habits and diet
Number of subjects: 1862

Group type: EXPERIMENTAL
Intervention: Patient-applied fluoride toothpaste
Number of subjects: 1862
Study: 25648739

Group type: EXPERIMENTAL
Intervention: Kefir drink
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (low-fat dairy products, maintenance energy intake)
Number of subjects: 75
Study: 24726172

Group type: EXPERIMENTAL
Intervention: Cemented fixation
Number of subjects: 168

Group type: COMPARATOR
Intervention: Cementless fixation
Number of subjects: 168
Study: 22293030

Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin 10/40 mg
Number of subjects: 250

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg
Number of subjects: 250
Study: 21400791

Group type: EXPERIMENTAL
Intervention: Atropine administration in traditional subarachnoid anesthesia (SA) protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional subarachnoid anesthesia (SA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atropine administration in traditional SA protocol
Number of subjects: 0
Study: 17591533

Group type: EXPERIMENTAL
Intervention: Lisinopril (ACE-inhibitor group; 36 patients)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No therapy (control group; 34 subjects)
Number of subjects: 70
Study: 15686584

Group type: EXPERIMENTAL
Intervention: Feelings of resource scarcity (poor or hungry)
Number of subjects: 1176

Group type: COMPARATOR
Intervention: Feelings of abundance (rich or full)
Number of subjects: 1176
Study: 12196421

Group type: EXPERIMENTAL
Intervention: High fiber cereal foods (19 g/day additional cereal fiber)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Low fiber supplements (4 g/day additional cereal fiber)
Number of subjects: 23
Study: 9869199

Group type: EXPERIMENTAL
Intervention: Low IL-6 and CRP serum levels (N=21)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Detectable IL-6 (N=10)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CRP <10 mg/l (N=unknown)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Higher CRP levels (N=5)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Univariate analysis of CRP and IL-6 levels
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CRP levels and B symptoms
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CRP and LDH levels
Number of subjects: 39
Study: 7888983

Group type: EXPERIMENTAL
Intervention: Citalopram (C) 40 mg/day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Citalopram (C)
Number of subjects: 62
Study: 2240139

Group type: EXPERIMENTAL
Intervention: Adjuvant immunotherapy with methanol-extracted residue of bacille Calmette-Guerin
Number of subjects: 113

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Adjuvant immunotherapy
Number of subjects: 113
Study: 365536

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Propranolol 120 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Propranolol 240 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Propranolol 320 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31827366

Group type: EXPERIMENTAL
Intervention: Plyometric Jump Training (PJT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 26
Study: 29443557

Group type: EXPERIMENTAL
Intervention: Power Through Choices (PTC) intervention
Number of subjects: 1036
Study: 27567824

Group type: EXPERIMENTAL
Intervention: Savvy Caregiver Program (SCP)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 164
Study: 24484944

Group type: EXPERIMENTAL
Intervention: Conventional Endoscopy Sinus Surgery (ESS)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Balloon Sinuplasty (BS)
Number of subjects: 83
Study: 21745436

Group type: EXPERIMENTAL
Intervention: GSK598809 (175 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 20559037

Group type: EXPERIMENTAL
Intervention: 7vPnC vaccine with CPG 7909 adjuvant
Number of subjects: 95

Group type: COMPARATOR
Intervention: 7vPnC vaccine with placebo adjuvant
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: HAART-treated individuals
Number of subjects: 95

Group type: COMPARATOR
Intervention: HAART-naive individuals
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: HAART use
Number of subjects: 95
Study: 17384858

Group type: EXPERIMENTAL
Intervention: 0.1% chlorine dioxide mouthrinse
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 14
Study: 16544524

Group type: EXPERIMENTAL
Intervention: Pregnancy-induced hypertension (PIH)
Number of subjects: 70
Study: 14574041

Group type: EXPERIMENTAL
Intervention: Catheter ablation of the atrioventricular node
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of the atrioventricular node with permanent pacing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focal atrial fibrillation ablation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Catheter ablation techniques for ventricular tachycardia
Number of subjects: 0
Study: 10673910

Group type: EXPERIMENTAL
Intervention: Inulin (up to 34 g/d)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control diet (devoid of inulin)
Number of subjects: 8
Study: 8707977

Group type: EXPERIMENTAL
Intervention: Coe-pak
Number of subjects: 0

Group type: COMPARATOR
Intervention: RD8
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both dressings
Number of subjects: 0
Study: 1518257

Group type: EXPERIMENTAL
Intervention: Modified ALL-BFM 81 protocol with late reinduction protocol III and therapy stopped after reinduction.
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Modified ALL-BFM 81 protocol with 6-MP and MTX for another six months after reinduction.
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Modified ALL-BFM 86 study with reduced MTX dosage from 5 g/m2 to 1 g/m2.
Number of subjects: 818

Group type: COMPARATOR
Intervention: Intermediate dose MTX (4 x 0.5 g/m2) in standard risk patients.
Number of subjects: 818
Study: 6434415

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 60
Study: 30851445

Group type: EXPERIMENTAL
Intervention: Face-to-face (FTF) communication mode with prior knowledge
Number of subjects: 2

Group type: COMPARATOR
Intervention: Computer-mediated communication (CMC) mode with prior knowledge
Number of subjects: 2

Group type: COMPARATOR
Intervention: Face-to-face (FTF) communication mode without prior knowledge
Number of subjects: 2

Group type: COMPARATOR
Intervention: Computer-mediated communication (CMC) mode without prior knowledge
Number of subjects: 2
Study: 28669290

Group type: EXPERIMENTAL
Intervention: Telemedicine-based collaborative care (TOP)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 265
Study: 25505191

Group type: EXPERIMENTAL
Intervention: Intranasal jasmine flower extract (JFE)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 35
Study: 24274963

Group type: EXPERIMENTAL
Intervention: Culturally adapted CBT (CaCBT) based self-help
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study: 21079512

Group type: EXPERIMENTAL
Intervention: Desirudin (15 or 30 mg every 12 hours)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Argatroban (activated partial thromboplastin time-adjusted by intravenous infusion)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Desirudin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 16

Group type: COMPARATOR
Intervention: Argatroban
Number of subjects: 16
Study: 19374294

Group type: EXPERIMENTAL
Intervention: Tranexamic acid, 250 mg four times a day for 5 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 17428479

Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 246
Study: 15682779

Group type: EXPERIMENTAL
Intervention: Community mobilization and outreach activities
Number of subjects: 2381
Study: 12605261

Group type: EXPERIMENTAL
Intervention: Sine Amsler Charts (SAC) preoperative testing
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sine Amsler Charts (SAC) postoperative testing
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Visual acuity postoperative
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Decrease in SAC score with increase in visual acuity
Number of subjects: 63
Study: 9435326

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (20 U)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study: 8033240

Group type: EXPERIMENTAL
Intervention: Sustained-release ketoprofen (SRK) in the morning (200 mg once a day)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Sustained-release ketoprofen (SRK) in the evening (200 mg once a day)
Number of subjects: 117
Study: 2755708

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Intramuscular injections on demand (i.m.)
Number of subjects: 88
Study: 73694

Group type: EXPERIMENTAL
Intervention: Experimental group (self-monitoring and reinforcement)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 31776595

Group type: EXPERIMENTAL
Intervention: Presence of the spot sign
Number of subjects: 57
Study: 30827166

Group type: COMPARATOR
Intervention: Off clamp robotic partial nephrectomy
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Shift robotic partial nephrectomy
Number of subjects: 301
Study: 28606216

Group type: EXPERIMENTAL
Intervention: 6.2 g/d n-3 PUFA (3.7 g EPA and 2.5 g DHA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 3.1 g/d n-3 PUFA (1.8 g EPA and 1.3 g DHA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 6.2 g/d n-3 PUFA
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 3.1 g/d n-3 PUFA
Number of subjects: 16
Study: 26205382

Group type: EXPERIMENTAL
Intervention: InTen‐S (reduced shrinkage stress resin composite)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Point 4 (microhybrid resin composite)
Number of subjects: 50
Study: 23258767

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 339

Group type: COMPARATOR
Intervention: Mirtazapine
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study: 21719095

Group type: EXPERIMENTAL
Intervention: 14-day full-dose teplizumab
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: 14-day low-dose teplizumab
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: 6-day full-dose teplizumab
Number of subjects: 516

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Teplizumab groups (combined)
Number of subjects: 516
Study: 19032601

Group type: EXPERIMENTAL
Intervention: L-NMMA (0.5 mg kg(‐1) min(‐1))
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L-Arg (0.5 mg kg(‐1) min(1))
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L-NMMA (0.03 mg kg(‐1) min(1))
Number of subjects: 20

Group type: COMPARATOR
Intervention: L-NMMA with saline (150 mL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: D-Arg
Number of subjects: 20
Study: 17368152

Group type: EXPERIMENTAL
Intervention: Bivalirudin plus glycoprotein IIb/IIIa inhibitors
Number of subjects: 7789

Group type: EXPERIMENTAL
Intervention: Bivalirudin alone
Number of subjects: 7789

Group type: COMPARATOR
Intervention: Heparin plus glycoprotein IIb/IIIa inhibitors
Number of subjects: 7789
Study: 15338070

Group type: EXPERIMENTAL
Intervention: H1-/H2-histamine antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histamine releaser compound 48/80
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histamine injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 11836849

Group type: EXPERIMENTAL
Intervention: Trimetazidine (40 mg bolus i.v. then 60 mg per day for 48 hours intravenously in glucose infusion)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9951746

Group type: EXPERIMENTAL
Intervention: Anticardiolipin antibody presence in Group 1 (recurrent spontaneous abortion)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Anticardiolipin antibody presence in Group 2 (fertile women)
Number of subjects: 156
Study: 8053971

Group type: EXPERIMENTAL
Intervention: Chlorpropamide 0.5 once daily morning
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tolbutamide 0.5 t.i.d.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Glibenclamide 0.005 t.i.d.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Glibornuride 0.025 t.i.d.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Glipizide 0.005 t.i.d.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control tests (not specified)
Number of subjects: 50
Study: 1960069

Group type: EXPERIMENTAL
Intervention: Preadmission and postadmission preoperative education
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine postadmission preoperative education
Number of subjects: 40
Study: 636970

Group type: EXPERIMENTAL
Intervention: Restricted manipulation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Free manipulation
Number of subjects: 60
Study: 31402142

Group type: EXPERIMENTAL
Intervention: Nonheterosexual identity
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Heterosexual identity
Number of subjects: 5000
Study: 29077150

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 60
Study: 26083702

Group type: EXPERIMENTAL
Intervention: Recreational skiing intervention (12 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 23
Study: 23216780

Group type: EXPERIMENTAL
Intervention: Fibrin pad (FP)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 104
Study: 21473965

Group type: EXPERIMENTAL
Intervention: Personalized risk communication
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard risk factor education
Number of subjects: 89
Study: 19864467

Group type: EXPERIMENTAL
Intervention: CO2 flushing (10L/min for 5 minutes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no CO2 flushing, contained air)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CO2 group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (after knocking on the reservoir at the 14th minute)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (15th minute)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CO2 group (15th minute)
Number of subjects: 20
Study: 17464605

Group type: EXPERIMENTAL
Intervention: Ropivacaine, ketorolac, and adrenaline wound infiltration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 40